AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Bluejay Diagnostics, a medical diagnostics company, provided a mid-year business update highlighting recent developments in its SYMON clinical program, regulatory pathway, manufacturing progress, and financial results. The company initiated the SYMON-II clinical study and plans to submit a 510(k) regulatory application to the FDA in Q4 2027. It also raised $3.8 million in April 2025 and is seeking further financing to raise at least $30 million.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet